CompletedNCT03287505
Aripiprazole Depot: Single-Dose Safety and Pharmacokinetics in China
About this title
Read the official source — NCT03287505This study evaluated the safety of Aripiprazole IM Depot for people with schizophrenia.
Medication studyAges 18–64China
Understand this study
What did researchers investigate?
This study evaluated the safety of Aripiprazole IM Depot for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- BeijingSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: June 23, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Otsuka Beijing Research Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- China
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT03287505
- Official title
Show the full official title
Evaluation of Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation by Single Administration in Chinese Patients With Schizophrenia: a Single-center, Uncontrolled, Open -Label Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Beijing
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety of Aripiprazole IM Depot for people with schizophrenia.
Who is behind this study?
The study sponsor is Otsuka Beijing Research Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole IM Depot.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
